Leerink Partners Resumes Thermo Fisher Scientific (TMO) at Outperform

Leerink Partners resumes coverage on Thermo Fisher Scientific (NYSE: TMO) with a Outperform rating and a price target of $175.00.

Analyst Puneet Souda commented, "We are resuming coverage of Thermo Fisher Scientific (TMO) with an Outperform rating and $175 price target. Thermo Fisher (TMO) is a life science tools leader with an unmatched scale and reach in the research labs market combined with a number of growth products serving key end-markets. TMO has established a solid reputation for execution, having acquired and integrated a number of tools and diagnostics companies in an actively consolidating environment. Given the scale and TMO’s strong positions across various markets, we remain confident that the company can deliver and possibly exceed its topline growth estimates of 4% - 6% and EPS growth of 12% - 15% over the next 3 years."

For an analyst ratings summary and ratings history on Thermo Fisher Scientific click here. For more ratings news on Thermo Fisher Scientific click here.

Shares of Thermo Fisher Scientific closed at $152.05 yesterday.

You May Also Be Interested In

• Midday movers: Tesla, Boeing rise; Uber, Old Dominion Freight fall
• Thermo Fisher lifts profit forecast as medical equipment demand improves
• Thermo Fisher Scientific (TMO) PT Raised to $615 at Barclays